Relmada Therapeutics has a 12-month low of $0.24 and a 12-month high of $6.38. The firm’s fifty day moving average is $0.35 and its 200 day moving average is $1.82.

In a challenging year for Relmada Therapeutics (NASDAQ:RLMD), the company's stock has plummeted to a 52-week low, trading at ...

Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder ValueCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: ...

In a volatile trading session, Relmada Therapeutics Inc. (NASDAQ:RLMD) stock has plunged to its 52-week low, reaching a price level of just $0.71. With a market capitalization ...

BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Thursday, Mizuho (NYSE:MFG) analysts maintained their Neutral rating on Relmada Therapeutics Inc (NASDAQ:RLMD), with a steady price target of $1.00, following the announcement of a new acquisition.

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone ...